Table II.
Study | p53 | CK AE 1/3 | EMA | SMA | MSA | Desmin | Vimentin | S-100 | CD 68 |
---|---|---|---|---|---|---|---|---|---|
Iczkowski et al (10) | 3/4 | 2/4 | 1/3 | 2/4 | 2/3 | 2/3 | 4/4 | 0/3 | ND |
Micci et al (7) | ND | ND | ND | ND | ND | ND | ND | ND | ND |
Spiess et al (11) | ND | 10/10 | ND | 10/10 | ND | ND | 10/10 | ND | 10/10 |
Montgomery et al (5) | ND | 1/1 | ND | ND | ND | ND | ND | ND | ND |
Lo et al (12) | 0/1 | 0/1 | 0/1 | 0/1 | ND | 0/1 | 1/1 | 0/1 | ND |
Wick et al (13) | ND | 2/2 | 0/2 | ND | 2/2 | 2/2 | 2/2 | 0/2 | ND |
Present case | ND | 1/1 | 0/1 | 1/1 | ND | 0/1 | 1/1 | 0/1 | ND |
Total | 3/5 | 16/19 | 1/7 | 13/16 | 4/5 | 4/7 | 18/18 | 0/7 | 10/10 |
CK AE 1/3, cytokeratin AE 1/3; EMA, epithelial membrane antigen; SMA, smooth muscle actin; MSA, muscle-specific actin; CD, cluster of differentiation; ND, no data.